Previous Page  7 / 20 Next Page
Information
Show Menu
Previous Page 7 / 20 Next Page
Page Background

Page 30

Notes:

&

24

th

Biotechnology Congress: Research & Innovations

CRISPR Cas9 Technology and Genetic Engineering

Annual Congress on

October 24-25, 2018 | Boston, USA

Journal of Biotechnology & Biomaterials | ISSN: 2155-952X | Volume: 8

Natural polymers of bacterial origin and their medical applications

Ipsita Roy

University of Westminster, UK

P

olyhydroxyalkanoates (PHAs) are natural polymers produced by bacteria under nutrient limiting conditions. These

polymers are biodegradable and biocompatible in nature and hence can be used in a variety of medical applications such

as tissue engineering, wound healing, medical device production, and drug delivery. PHA synthases are the main enzymes

involved in the biosynthesis of PHAs. There are two main types of PHAs, short chain length PHAs, scl-PHAs, with monomer

chain length C3-C5, these are generally hard and brittle; mcl-PHAs, with monomer chain length C

6

-C

16

, these are soft and

elastomeric in nature. Due to their varied mechanical properties and degradation rates, PHAs can be used to replace a range of

tissue types including bone nerve cartilage pancreas cardiac and skin. In addition they can be used for short-term and long-term

controlled drug delivery. PHAs are known to be particularly cardio-regenerative in nature. Myocardial infarction results in the

generation of scar tissue with limited or no regeneration. The concept of a cardiac patch is tailored to meet the unmet medical

need of cardiac regeneration where a biomaterial-based patch with/without cells would be used to induce efficient cardiac

regeneration. Mcl-PHAs have been shown to be excellent substrates for the growth and function of neonatal cardiomyocytes.

We have carried out an in-depth study of the potential of MCL-PHAs for the development of functional cardiac patches.PHAs

are also known to be highly neuro-regenerative in nature. Peripheral nerve injuries caused due to accident or disease are highly

debilitating in nature. Gaps longer than 5mm do not regenerate naturally and lead to loss of function. We have developed

Nerve guidance conduits using PHA based blends. These have been tested using animal models and were found to result in

functional regeneration comparable to autografts, an excellent

outcome.In

conclusion, PHAs are a highly promising family of

medical polymers with huge potential in the future.

Biography

Ipsita Roy is an expert in Microbial Biotechnology, Biomaterials and Tissue Engineering. She is currently a Professor at the Faculty of Science and Technology,

University of Westminster, London. She was awarded the Inlaks Scholarship to study for her PhD at the University of Cambridge. Her postdoctoral work was at

the University of Minnesota, USA. Subsequently, she has been at the University of Westminster since 2000 and leads the Applied Biotechnology Research Group.

She has published over 100 papers in high Impact Factor journals such as Biomaterials, Biomacromolecules, Journal of Royal Society Interface. Her group is

currently focussed on the production of novel polyhydroxyalkanoates (PHAs), a group of FDA-approved natural polymers and their characterisation. Her work has

been funded by the EPSRC, EU, DuPont and WESTFOCUS, London. Professor Roy’s current projects involve the use of PHAs for the production of drug eluting

biodegradable stents, nerve guidance conduits, antibacterial polymers and wound healing.

royi@

wmin.ac.uk

Ipsita Roy, J Biotechnol Biomater 2018, Volume 8

DOI: 10.4172/2155-952X-C4-097